DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Novolimus Eluting Coronary Bioadaptor System

Inclusion Criteria:

1. Over 18 years of age
2. Patient understands the trial requirements and treatment procedures and providesinformed consent
3. Patient indicated for PCI with stent implantation and receive at least one DynamXBioadaptor implant in accordance with the product's Instructions for Use (IFU).

Exclusion Criteria:

1. Target Lesion(s) in the left main artery
2. Prior venous or arterial bypass grafts
3. In-stent restenosis
4. Patient is currently participating in another clinical trial with an investigationaldevice or an investigational drug that has the potential to impact study results (e.g., anti-thrombotic or anti-platelet medications) that has not yet completed itsprimary endpoint
5. Patient is, in the opinion of the Investigator, unable to comply with the requirementsof the study protocol or is unsuitable for the registry for any reason